Business context and reporting period
This filing is Stellar Biotechnologies, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2016, covering the three- and nine-month periods ended that date. It is not an Edesa Biotech filing; the supplied filing identifies Stellar Biotechnologies as the registrant. Stellar develops, manufactures and commercializes Keyhole Limpet Hemocyanin (KLH) for biotechnology, pharmaceutical, research and clinical markets.
Financial performance and position
| Metric | Three months ended June 30, 2016 | Nine months ended June 30, 2016 | Comparison |
|---|---|---|---|
| Revenue | $181,092 | $995,587 | Prior-year periods: $157,748 and $558,036 |
| Net income (loss) | $(1,194,077) | $(3,684,890) | Prior-year periods: $463,986 income and $(1,305,655) loss |
| Basic loss per share | $(0.14) | $(0.44) | Prior-year periods: $0.06 income and $(0.16) loss per share |
| Total expenses | $1,369,570 | $4,587,362 | Prior-year periods: $1,033,333 and $3,948,669 |
| Operating cash used | Not separately presented | $3,313,962 | Prior-year nine months: $3,497,293 used |
- Nine-month product sales were $963,587, up from $408,036; contract-services revenue declined to $32,000 from $150,000.
- At June 30, cash and cash equivalents were $4,787,203, short-term investments $1,999,081, and working capital $6,887,427. Total assets were $8,500,018; current liabilities were $839,002. The filing reports no outstanding warrant liability and no debt balance.
- Cash increased $831,700 from September 30, 2015. Investing activities provided $2,654,537 and financing activities provided $1,368,260, primarily from warrant exercises.
- Gross margin is not stated as a separate measure. The statement presents cost of sales and contract services and aquaculture costs separately.
Material changes versus prior comparable periods
- Nine-month revenue rose 78% year over year, largely from higher KLH product sales, while contract-services revenue fell following completion of collaboration and supply-agreement work.
- Nine-month net loss widened to $3.7 million from $1.3 million. The comparison is significantly affected by noncash warrant fair-value results: a $211,956 loss in 2016 versus a $2,455,361 gain in 2015. All warrants with Canadian-dollar exercise prices had been exercised or expired by October 2015, leaving no warrant liability at June 30, 2016.
- Nine-month R&D expense increased to $1,068,008 from $830,115, reflecting KLH research and process development and the Baja California aquaculture feasibility assessment. General and administrative expense rose to $2,595,176 from $2,346,019.
Outlook, risks and unusual items
- Management expected existing resources to support current initiatives and obligations for at least 12 months and said working capital was adequate for anticipated spending. It also expected continued losses and noted possible future financing needs; no new financing commitment had been secured as of the filing.
- After quarter-end, a registered direct offering and concurrent private placement closed July 6, 2016: 1,687,500 shares sold at $4.00 each and warrants for up to 1,265,625 shares issued at a $4.50 exercise price. Gross proceeds were $6.75 million and net proceeds approximately $6.0 million. The company reported 10,136,258 shares outstanding as of August 5, 2016.
- In May 2016, Stellar agreed to a 30% interest in a Neovacs joint venture for an initial contribution of €120,000; approximately $67,000 had been paid by June 30, with the balance due upon specified events. Additional pro-rata funding may be required. Related supply, service and license agreements had not yet been executed at quarter-end; specified milestones could lead to dissolution by December 2017.
- Revenue and receivables are concentrated: 91% of nine-month revenue came from five customers, and 82% of June 30 receivables were due from two customers. The company also disclosed lease payments of about $511,000 and research/consulting commitments of about $340,000, plus estimated contractor commitments of about $5,000.
- Management reported effective disclosure controls, no material change in internal control over financial reporting, no material legal proceedings outside the ordinary course, and no material changes to previously disclosed risk factors. It identified foreign exchange, credit concentration and liquidity as market risks.
Investor verification points
- Confirm the registrant and reporting period: this source is Stellar Biotechnologies’ June 30, 2016 10-Q, not an Edesa Biotech filing.
- Review the July 2016 offering documents and subsequent share count, including the potential dilution from the 1,265,625 warrants.
- Assess cash runway against continuing operating losses, planned R&D, lease and purchase obligations, and the company’s stated financing alternatives.
- Examine customer concentration and the execution, funding obligations and milestone status of the Neovacs joint venture.
- Separate recurring operating results from noncash warrant fair-value changes when evaluating year-over-year losses.